Rocket Pharmaceuticals - Public Comps and Valuation Multiples

Rocket Pharmaceuticals Overview

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Founded

1999

HQ

Employees

299

Website

rocketpharma.com

Sectors

Drug Development & Therapeutics
Regenerative Medicine
BioTech

Financials

Last FY Revenue n/a

LTM EBITDA -$222M

EV

$144M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Rocket Pharmaceuticals Financials

As of November 2025, Rocket Pharmaceuticals reported last 12-month EBITDA of -$222M.

In the same period, Rocket Pharmaceuticals achieved -$228M in LTM net income.

See Rocket Pharmaceuticals valuation multiples based on analyst estimates

Rocket Pharmaceuticals P&L

In the most recent fiscal year, Rocket Pharmaceuticals reported EBITDA of -$247M.

Rocket Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Rocket Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$222M	XXX	-$247M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$238M	XXX	-$273M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$228M	XXX	-$259M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Rocket Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$222M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$222M	Analyst estimates available to subscribers	-$247M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$238M	Analyst estimates available to subscribers	-$273M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$228M	Analyst estimates available to subscribers	-$259M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Rocket Pharmaceuticals

This financial data table provides comprehensive performance metrics for Rocket Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$222M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$228M.

Fiscal Year Performance

Fiscal year EBITDA was -$247M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Rocket Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals has current market cap of $342M, and EV of $144M.

Market Cap Evolution

Rocket Pharmaceuticals Stock Data

As of December 3, 2025, Rocket Pharmaceuticals's stock price is $3.

See Rocket Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$144M	$342M	XXX	XXX	XXX	XXX	$-2.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Rocket Pharmaceuticals Valuation Multiples

Rocket Pharmaceuticals's trades at n/a EV/Revenue multiple, and -0.6x EV/EBITDA.

See valuation multiples for Rocket Pharmaceuticals and 15K+ public comps

Rocket Pharmaceuticals Financial Valuation Multiples

As of December 3, 2025, Rocket Pharmaceuticals has market cap of $342M and EV of $144M.

Equity research analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Rocket Pharmaceuticals has a P/E ratio of -1.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$342M	XXX	$342M	XXX	XXX	XXX
EV (current)	$144M	XXX	$144M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-0.6x	XXX	-0.6x	XXX	XXX	XXX
EV/EBIT	-0.6x	XXX	-0.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-1.5x	XXX	-1.3x	XXX	XXX	XXX
EV/FCF	-0.7x	XXX	-0.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rocket Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Rocket Pharmaceuticals Margins & Growth Rates

Rocket Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.

Rocket Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rocket Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Rocket Pharmaceuticals and other 15K+ public comps

Rocket Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	-28%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial